Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20521691 | 0.90 | NPC1 (0.32) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL19615379 | 0.89 | KDM4C (0.39) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL21802183 | 0.81 | MEN1 (0.39) | MEN1KMT2ARAB9A | |
| SCHEMBL20521946 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL19635898 | 0.78 | TSHR (0.37) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL29601953 | 0.78 | TSHR (0.37) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL24524630 | 0.76 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL20522195 | 0.74 | ADORA3 (0.31) | KDM4C | |
| SCHEMBL20521904 | 0.74 | — | — | |
| SCHEMBL22437573 | 0.74 | KDM4C (0.34) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| WO-2018178226-A1 | MCL-1 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2018-10-04 | — | — | WO | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11492358-B1 | Macrocyclic indole derivatives | CCND2, CCNT2, IDO1 | MEN1 142/4885KMT2A 930/4885KDM4C 1522/4885 |
| US-10981932-B2 | Macrocyclic indole derivatives | CCND2, IDO1, CCNT2 | MEN1 114/4885KMT2A 772/4885KDM4C 1429/4885 |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | CCND2, CCNA1, CCNT2 | MEN1 140/4885KMT2A 897/4885KDM4C 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.